Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Comment by HopefulJuanon Oct 07, 2020 8:57am
257 Views
Post# 31679107

RE:Aphria Finally Completes First Cannabis Shipment To Germany

RE:Aphria Finally Completes First Cannabis Shipment To Germany

Nobody Knows How Many Patients There Actually Are: By industry estimates and reports drawn from the public reporting of Germany’s association of public health insurers (GKV), there have been about 100,000 applications so far since 2017 to the major statutory health insurers (who cover 90% of the population). Of these, it is estimated that there are about 60,000 regular patients. The amount of actual patients however is currently unknown.

When one counts the actual number of activist patients, those who are buying and or cultivating in collectives, or who go to the black market out of sheer frustration in getting a doctor to write a prescription (or affording flower in a pharmacy), the pool of real patients in Germany is much, much larger.

Further medical reform here is clearly in the offing no matter how slow. And no matter how delayed German grown cannabis has been here, it is coming – distributed via one specialty distributor in Frankfurt. 

A former health minister and vice-chancellor of Germany also just made waves, if not a strong political statement when he recently joined the board of a Swiss cannabis company.

Imports Will Continue To Play A Large Role: There is no doubt in anyone’s mind that exports from the rest of the world (and increasingly, NOT Canada) are entering the German medical market.

<< Previous
Bullboard Posts
Next >>